دورية أكاديمية
Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study
| العنوان: | Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study |
|---|---|
| المؤلفون: | Sava, Mihaela, Sommer, Gregor, Daikeler, Thomas, Woischnig, Anne-Kathrin, Martinez, Aurelien E, Leuzinger, Karoline, Hirsch, Hans, Erlanger, Tobias, Wiencierz, Andrea, Bassetti, Stefano, Tamm, Michael, Tschudin-Sutter, Sarah, Stoeckle, Marcel, Pargger, Hans, Siegemund, Martin, Boss, Renate, Zimmer, Gert, Vu Cantero, Diem-Lan, Kaiser, Laurent, Dell-Kuster, Salome, Weisser, Maja, Battegay, Manuel, Hostettler, Katrin, Khanna, Nina |
| المصدر: | ISSN: 0036-7672 ; Swiss medical weekly, vol. 151 (2021) w20550. |
| سنة النشر: | 2021 |
| المجموعة: | Université de Genève: Archive ouverte UNIGE |
| مصطلحات موضوعية: | info:eu-repo/classification/ddc/616, Antibodies, Monoclonal, Humanized, COVID-19 / drug therapy, Cohort Studies, Humans, Prospective Studies, SARS-CoV-2 |
| الوصف: | Objectives: Patients with severe COVID-19 may be at risk of longer term sequelae. Long-term clinical, immunological, pulmonary and radiological outcomes of patients treated with anti-inflammatory drugs are lacking. Methods: In this single-centre prospective cohort study, we assessed 90-day clinical, immunological, pulmonary and radiological outcomes of hospitalised patients with severe COVID-19 treated with tocilizumab from March 2020 to May 2020. Criteria for tocilizumab administration were oxygen saturation <93%, respiratory rate >30/min, C-reactive protein levels >75 mg/l, extensive area of ground-glass opacities or progression on computed tomography (CT). Descriptive analyses were performed using StataIC 16. Results: Between March 2020 and May 2020, 50 (27%) of 186 hospitalised patients had severe COVID-19 and were treated with tocilizumab. Of these, 52% were hospitalised on the intensive care unit (ICU) and 12% died. Eleven (22%) patients developed at least one microbiologically confirmed super-infection, of which 91% occurred on ICU. Median duration of hospitalisation was 15 days (interquartile range [IQR] 10–24) with 24 days (IQR 14–32) in ICU patients and 10 days (IQR 7–15) in non-ICU patients. At day 90, 41 of 44 survivors (93%) were outpatients. No long-term adverse events or late-onset infections were identified after acute hospital care. High SARS-CoV-2 antibody titres were found in all but one patient, who was pretreated with rituximab. Pulmonary function tests showed no obstructive patterns, but restrictive patterns in two (5.7%) and impaired diffusion capacities for carbon monoxide in 11 (31%) of 35 patients, which predominated in prior ICU patients. Twenty-one of 35 (60%) CT-scans at day 90 showed residual abnormalities, with similar distributions between prior ICU and non-ICU patients. Conclusions: In this cohort of severe COVID-19 patients, no tocilizumab-related long-term adverse events or late-onset infections were identified. Although chest CT abnormalities were highly prevalent at ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34375986; info:eu-repo/semantics/dataset/url/https://clinicaltrials.gov/ct2/show/NCT04351503Test; https://archive-ouverte.unige.ch/unige:162888Test; unige:162888 |
| الإتاحة: | https://doi.org/10.4414/smw.2021.20550Test https://archive-ouverte.unige.ch/unige:162888Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.27784B30 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |